Leerink Partnrs Comments on Nkarta FY2029 Earnings

Nkarta, Inc. (NASDAQ:NKTX) – Leerink Partnrs issued their FY2029 EPS estimates for Nkarta in a report issued on Thursday, February 13th. Leerink Partnrs analyst D. Graybosch anticipates that the company will post earnings per share of ($1.74) for the year. The consensus estimate for Nkarta’s current full-year earnings is ($1.68) per share.

NKTX has been the topic of a number of other research reports. HC Wainwright cut their target price on shares of Nkarta from $22.00 to $18.00 and set a “buy” rating on the stock in a research note on Monday, November 11th. Mizuho cut their target price on shares of Nkarta from $20.00 to $16.00 and set an “outperform” rating on the stock in a research note on Thursday, November 21st. Finally, Needham & Company LLC cut their target price on shares of Nkarta from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $15.00.

Nkarta Stock Up 4.2 %

NASDAQ:NKTX opened at $2.21 on Friday. The firm’s 50 day moving average is $2.35 and its two-hundred day moving average is $3.62. Nkarta has a fifty-two week low of $1.96 and a fifty-two week high of $16.24. The company has a market cap of $155.96 million, a P/E ratio of -1.18 and a beta of 0.85.

Institutional Investors Weigh In On Nkarta

A number of large investors have recently added to or reduced their stakes in the company. Wasatch Advisors LP grew its holdings in Nkarta by 31.7% during the 3rd quarter. Wasatch Advisors LP now owns 1,834,680 shares of the company’s stock worth $8,293,000 after acquiring an additional 442,125 shares in the last quarter. Geode Capital Management LLC grew its holdings in Nkarta by 3.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,171,026 shares of the company’s stock worth $5,294,000 after acquiring an additional 33,927 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in Nkarta by 252.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,063,362 shares of the company’s stock worth $4,806,000 after acquiring an additional 761,349 shares in the last quarter. Franklin Resources Inc. acquired a new position in Nkarta during the 3rd quarter worth $151,000. Finally, FMR LLC grew its holdings in Nkarta by 97.1% during the 3rd quarter. FMR LLC now owns 133,149 shares of the company’s stock worth $602,000 after acquiring an additional 65,600 shares in the last quarter. 80.54% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Nkarta

In related news, CEO Paul J. Hastings sold 17,378 shares of the firm’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total transaction of $38,231.60. Following the completion of the sale, the chief executive officer now directly owns 319,859 shares of the company’s stock, valued at approximately $703,689.80. This trade represents a 5.15 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 8.70% of the company’s stock.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.